Proteus Syndrome - Pipeline Insight, 2019
This report can be delivered to the clients within 24 Hours
"Proteus Syndrome - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Proteus Syndrome pipeline landscape is provided which includes the disease overview and Proteus Syndrome treatment guidelines. The assessment part of the report embraces, in depth Proteus Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Proteus Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Proteus Syndrome Understanding
"Proteus syndrome also known as (Wiedemann syndrome; Elephant Man's disease) is a rare condition characterized by overgrowth of the bones, skin, and other tissues. Organs and tissues affected by the disease grow out of proportion to the rest of the body. The overgrowth is usually asymmetric, which means it affects the right and left sides of the body differently. Newborns with Proteus syndrome have few or no signs of the condition. Overgrowth becomes apparent between the ages of 6 and 18 months and gets more severe with age. In people with Proteus syndrome, the pattern of overgrowth varies greatly but can affect almost any part of the body. Bones in the limbs, skull, and spine are often affected. The condition can also cause a variety of skin growths, particularly a thick, raised, and deeply grooved lesion known as a cerebriform connective tissue nevus. This type of skin growth usually occurs on the soles of the feet and is hardly ever seen in conditions other than Proteus syndrome. Blood vessels (vascular tissue) and fat (adipose tissue) can also grow abnormally in Proteus syndrome.
Proteus Syndrome Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Proteus Syndrome targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Proteus Syndrome pipeline report covers only one company. The only key player include ArQule (Miransertib) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Proteus Syndrome Analytical Perspective by DelveInsight
Scope of the report
"Proteus Syndrome - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Proteus Syndrome pipeline landscape is provided which includes the disease overview and Proteus Syndrome treatment guidelines. The assessment part of the report embraces, in depth Proteus Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Proteus Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Proteus Syndrome Understanding
"Proteus syndrome also known as (Wiedemann syndrome; Elephant Man's disease) is a rare condition characterized by overgrowth of the bones, skin, and other tissues. Organs and tissues affected by the disease grow out of proportion to the rest of the body. The overgrowth is usually asymmetric, which means it affects the right and left sides of the body differently. Newborns with Proteus syndrome have few or no signs of the condition. Overgrowth becomes apparent between the ages of 6 and 18 months and gets more severe with age. In people with Proteus syndrome, the pattern of overgrowth varies greatly but can affect almost any part of the body. Bones in the limbs, skull, and spine are often affected. The condition can also cause a variety of skin growths, particularly a thick, raised, and deeply grooved lesion known as a cerebriform connective tissue nevus. This type of skin growth usually occurs on the soles of the feet and is hardly ever seen in conditions other than Proteus syndrome. Blood vessels (vascular tissue) and fat (adipose tissue) can also grow abnormally in Proteus syndrome.
Proteus Syndrome Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Proteus Syndrome targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Proteus Syndrome pipeline report covers only one company. The only key player include ArQule (Miransertib) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Proteus Syndrome Analytical Perspective by DelveInsight
- In-depth Proteus Syndrome Commercial Assessment of products
- Proteus Syndrome Clinical Assessment of products
Scope of the report
- The Proteus Syndrome report provides an overview of therapeutic pipeline activity for Proteus Syndrome across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Proteus Syndrome therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
- Detailed Proteus Syndrome Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Proteus Syndrome
- Establish a comprehensive understanding of the current pipeline scenario across Proteus Syndrome to formulate effective R&D strategies
- Assess challenges and opportunities that influence Proteus Syndrome R&D
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Get in detail information of each product with updated information on each project along with key milestones
- Devise Proteus Syndrome in licensing and out licensing strategies by identifying prospective partners with progressing projects for Proteus Syndrome to enhance and expand business potential and scope
- Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION
2. PROTEUS SYNDROME (WIEDEMANN SYNDROME) (ELEPHANT MAN'S DISEASE)
2.1. Proteus Syndrome Disease Overview
2.2. Proteus Syndrome History
2.3. Proteus Syndrome Symptoms
2.4. Proteus Syndrome Causes
2.5. Proteus Syndrome Pathophysiology
2.6. Proteus Syndrome Diagnosis
2.6.1. Diagnostic Guidelines
3. PROTEUS SYNDROME CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. PROTEUS SYNDROME - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Proteus Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Proteus Syndrome Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Proteus Syndrome Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. PROTEUS SYNDROME PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. PROTEUS SYNDROME -PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. Miransertib- ArQule
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.1.4. Product Development Activities
6.1.1.4.1. Tabulated Product Summary
6.1.1.4.1.1. General Description Table
To be continued in the report…………………………
7. RECENT TECHNOLOGIES
8. PROTEUS SYNDROME KEY COMPANIES
8.1. ArQule
9. PROTEUS SYNDROME KEY PRODUCTS
9.1. Miransertib
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. PROTEUS SYNDROME - UNMET NEEDS
12. PROTEUS SYNDROME - FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
2. PROTEUS SYNDROME (WIEDEMANN SYNDROME) (ELEPHANT MAN'S DISEASE)
2.1. Proteus Syndrome Disease Overview
2.2. Proteus Syndrome History
2.3. Proteus Syndrome Symptoms
2.4. Proteus Syndrome Causes
2.5. Proteus Syndrome Pathophysiology
2.6. Proteus Syndrome Diagnosis
2.6.1. Diagnostic Guidelines
3. PROTEUS SYNDROME CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. PROTEUS SYNDROME - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Proteus Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Proteus Syndrome Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Proteus Syndrome Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. PROTEUS SYNDROME PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. PROTEUS SYNDROME -PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. Miransertib- ArQule
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.1.4. Product Development Activities
6.1.1.4.1. Tabulated Product Summary
6.1.1.4.1.1. General Description Table
To be continued in the report…………………………
7. RECENT TECHNOLOGIES
8. PROTEUS SYNDROME KEY COMPANIES
8.1. ArQule
9. PROTEUS SYNDROME KEY PRODUCTS
9.1. Miransertib
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. PROTEUS SYNDROME - UNMET NEEDS
12. PROTEUS SYNDROME - FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
LIST OF TABLES
Table 1. Proteus Syndrome Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Proteus Syndrome Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
Table 1. Proteus Syndrome Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Proteus Syndrome Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
LIST OF FIGURES
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Proteus Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Proteus Syndrome Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
ArQule
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Proteus Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Proteus Syndrome Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
ArQule
